We are live on ! Find out more
BCM

Biomark Capital Management Portfolio holdings

AUM $8.9M
1-Year Est. Return 97.06%
This Fund
S&P 500
This Quarter Est. Return
+43.16%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.61M
AUM Growth
-$83.2M
Cap. Flow
-$85.2M
Cap. Flow %
-1,289.9%
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
JUNO
Juno Therapeutics, Inc.
JUNO
+$85.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
1
ADMA Biologics
ADMA
$1.96B
$6.59M 99.8%
1,433,304
– –
MBVX
2
DELISTED
MABVAX THERAPEUTICS HLDGS INC
MBVX
$13K 0.2%
8,903
– –
JUNO
3
DELISTED
Juno Therapeutics, Inc.
JUNO
– –
-1,864,174
Closed -$85.2M

Similar funds

OBP
Old Bellows Partners New York $9.01M AUM 83.84% 1-Year Est. Return
HC
Highstar Capital New York $8.59M AUM 3.82% 1-Year Est. Return
SBA
Seven Bridges Advisors New York $9.75M AUM 16.73% 1-Year Est. Return
CIG
Candlewood Investment Group Rye, New York $10.1M AUM 30% 1-Year Est. Return
LRM
Lime Rock Management Westport, Connecticut $7.54M AUM 22.09% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
GA
Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return
CCM
Catalus Capital Management Greenwich, Connecticut $6.09M AUM 3.76% 1-Year Est. Return

Biomark Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Biomark Capital Management held 3 positions worth $6.61M, down 93% from $89.8M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Biomark Capital Management withdrew a net $85.2M in Q1 2018, closing 1 position. Its most notable exit was Juno Therapeutics, Inc., an estimated $85.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 5.1% a quarter earlier.

  • Biomark Capital Management fully exited Juno Therapeutics, Inc. in Q1 2018, selling an estimated $85.2M.
  • Biomark Capital Management's ten largest holdings make up 100% of its $6.61M portfolio in Q1 2018.
  • Biomark Capital Management opened 0 new positions and closed 1 in Q1 2018.
  • Biomark Capital Management's portfolio value fell 93% quarter-over-quarter to $6.61M.

Based on Biomark Capital Management's 13F filing for Q1 2018, filed 20 Apr 2018.